Clinicopathologic case report: scleral buckle associated nontuberculous mycobacterial scleritis

Nielsen, Jared S.; Blatt, Stephen P.; Perlman, Jay I.; Gieser, Richard G.

doi:10.1080/08820530490882517

Cited by 13 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case reports and series from other ocular sites have been rare (Gupta et al 2003; Wilhelmus 2003; Nielsen et al 2004; Spencer et al 2005; Matieli et al 2006). Treatment strategies include amikacin and clarithromycin (Wilhelmus 2003).…”

Section: Spectrum Of Activitymentioning

confidence: 99%

Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections

Miller¹

2008

OPTH

View full text Add to dashboard Cite

Moxifloxacin hydrochloride ophthalmic solution 0.5% (Vigamox®) is the ocular formulation/adaptation of moxifloxacin. Moxifloxacin is a broad spectrum 8-methoxyfluoroquinolone which terminates bacterial growth by binding to DNA gyrase (topoisomerase II) and topoisomerase IV, essential bacterial enzymes involved in the replication, translation, repair and recombination of deoxyribonucleic acid. Affinity for both enzymes improves potency and reduces the probability of selecting resistant bacterial subpopulations. Vigamox is a bactericidal, concentration dependent, anti-infective. It is preservative free, and well tolerated with minimal ocular side effects. It provides increased penetration into ocular tissues and fluids with improved activity against Streptococci and Staphylococci species and moderate to excellent activity against clinically relevant, gram-negative ocular pathogens.

show abstract

Section: Spectrum Of Activitymentioning

confidence: 99%

Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections

Miller¹

2008

OPTH

View full text Add to dashboard Cite

show abstract

“…Typical signs and symptoms include irritation, discomfort, discharge, chemosis, and injection. Less common signs of infection include intraocular inflammation,17 scleritis,18 and conjunctival granuloma 19…”

Section: Discussionmentioning

confidence: 99%

Orbital cellulitis following silicone-sponge scleral buckles

Nemet¹,

Ferencz²,

Segal³

et al. 2013

OPTH

View full text Add to dashboard Cite

BackgroundAcute or chronic infection of the scleral explant is rare. We report seven cases of scleral explant infections that caused orbital cellulitis.Materials and methodsThis was a retrospective chart review of oculoplastics at oculoplastics and vitreo-retinal units in a secondary referral hospital. All subjects had orbital cellulitis secondary to scleral buckle in the range of January 1990 to March 2010. Demographics, imaging studies, and pathology specimens were reviewed.ResultsA total of 841 silicone-sponge scleral buckle implants for rhegmatogenous retinal detachment were performed. Forty were extracted (4.75%; annual rate of 1.9 cases). Seven (0.83%) had orbital cellulitis. The mean time from implantation to presentation was 5.7 years. There was bacterial growth in all specimens, with Staphylococcus aureus in four.ConclusionsPatients who are operated on with silicone-sponge scleral buckling for rhegmatogenous retinal detachment sometimes require removal of the implant because of infection. However, the infection rate is low. Patients should be followed in the long term for possible complications.

show abstract

“…The flora of the eyelids and conjunctiva are one major source of bacterial contamination of scleral buckles (15). The microorganisms involved in scleral buckle infections include a majority of staphylococci (17) followed by pseudomonas, proteus (15,(18)(19)(20), atypical mycobacteria (21)(22)(23)(24), and fungi (25,26). The conjunctiva grew coagulase-positive staphylococci (Case 3), coagulase-negative staphylococci (Case 4), and pseudomonas (Cases 14 and 15), in addition to the buckle growing Aspergillus in one case (Case 12).…”

Section: Discussionmentioning

confidence: 99%